These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29871931)

  • 1. Interleukin-like EMT inducer (ILEI) promotes melanoma invasiveness and is transcriptionally up-regulated by upstream stimulatory factor-1 (USF-1).
    Noguchi K; Dincman TA; Dalton AC; Howley BV; McCall BJ; Mohanty BK; Howe PH
    J Biol Chem; 2018 Jul; 293(29):11401-11414. PubMed ID: 29871931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
    Noguchi K; Dalton AC; Howley BV; McCall BJ; Yoshida A; Diehl JA; Howe PH
    PLoS One; 2017; 12(5):e0177830. PubMed ID: 28545079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness.
    Schmidt U; Heller G; Timelthaler G; Heffeter P; Somodi Z; Schweifer N; Sibilia M; Berger W; Csiszar A
    J Exp Clin Cancer Res; 2021 Feb; 40(1):69. PubMed ID: 33596971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ubiquitin ligase UBE4A inhibits prostate cancer progression by targeting interleukin-like EMT inducer (ILEI).
    Sun Y; Jia X; Gao Q; Liu X; Hou L
    IUBMB Life; 2017 Jan; 69(1):16-21. PubMed ID: 27862841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interleukin-like epithelial-mesenchymal transition inducer ILEI exhibits a non-interleukin-like fold and is active as a domain-swapped dimer.
    Jansson AM; Csiszar A; Maier J; Nyström AC; Ax E; Johansson P; Schiavone LH
    J Biol Chem; 2017 Sep; 292(37):15501-15511. PubMed ID: 28751379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent dimerization of interleukin-like epithelial-to-mesenchymal transition (EMT) inducer (ILEI) facilitates EMT, invasion, and late aspects of metastasis.
    Kral M; Klimek C; Kutay B; Timelthaler G; Lendl T; Neuditschko B; Gerner C; Sibilia M; Csiszar A
    FEBS J; 2017 Oct; 284(20):3484-3505. PubMed ID: 28837266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGFβ promotes breast cancer stem cell self-renewal through an ILEI/LIFR signaling axis.
    Woosley AN; Dalton AC; Hussey GS; Howley BV; Mohanty BK; Grelet S; Dincman T; Bloos S; Olsen SK; Howe PH
    Oncogene; 2019 May; 38(20):3794-3811. PubMed ID: 30692635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILEI: a novel marker for epithelial-mesenchymal transition and poor prognosis in colorectal cancer.
    Gao ZH; Lu C; Wang ZN; Song YX; Zhu JL; Gao P; Sun JX; Chen XW; Wang MX; Dong YL; Xu HM
    Histopathology; 2014 Oct; 65(4):527-38. PubMed ID: 24738665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549.
    Song Q; Sheng W; Zhang X; Jiao S; Li F
    Tumour Biol; 2014 Feb; 35(2):1377-82. PubMed ID: 24072492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ILEI is an important intermediate participating in the formation of TGF-β1-induced renal tubular EMT.
    Zhao X; Luo G; Fan Y; Ma X; Zhou J; Jiang H
    Cell Biochem Funct; 2018 Mar; 36(2):46-55. PubMed ID: 29336056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression.
    Lahsnig C; Mikula M; Petz M; Zulehner G; Schneller D; van Zijl F; Huber H; Csiszar A; Beug H; Mikulits W
    Oncogene; 2009 Feb; 28(5):638-50. PubMed ID: 19015638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCBP1 regulates LIFR through FAM3C to maintain breast cancer stem cell self-renewal and invasiveness.
    Streitfeld WS; Dalton AC; Howley BV; Howe PH
    Cancer Biol Ther; 2023 Dec; 24(1):2271638. PubMed ID: 37927213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells.
    Waerner T; Alacakaptan M; Tamir I; Oberauer R; Gal A; Brabletz T; Schreiber M; Jechlinger M; Beug H
    Cancer Cell; 2006 Sep; 10(3):227-39. PubMed ID: 16959614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and initial characterization of the BRCA2 promoter.
    Davis PL; Miron A; Andersen LM; Iglehart JD; Marks JR
    Oncogene; 1999 Oct; 18(44):6000-12. PubMed ID: 10557089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells.
    Chang JT; Yang HT; Wang TC; Cheng AJ
    Mol Carcinog; 2005 Nov; 44(3):183-92. PubMed ID: 16010690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of Delta-like 3 restricts lipopolysaccharide-induced inflammation, migration and invasion of A2058 melanoma cells via blocking Twist1-mediated epithelial-mesenchymal transition.
    Ding X; Li F; Zhang L
    Life Sci; 2019 Jun; 226():149-155. PubMed ID: 30981764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
    Csiszar A; Kutay B; Wirth S; Schmidt U; Macho-Maschler S; Schreiber M; Alacakaptan M; Vogel GF; Aumayr K; Huber LA; Beug H
    Breast Cancer Res; 2014 Sep; 16(5):433. PubMed ID: 25212966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT.
    Kosnopfel C; Sinnberg T; Sauer B; Busch C; Niessner H; Schmitt A; Forchhammer S; Grimmel C; Mertens PR; Hailfinger S; Dunn SE; Garbe C; Schittek B
    Mol Cancer Res; 2018 Jul; 16(7):1149-1160. PubMed ID: 29743296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural analysis of factors related to FAM3C/ILEI dimerization and identification of inhibitor candidates targeting cancer treatment.
    Flores RMA; Pantaleão SQ; Araujo SC; Malpartida HMG; Honorio KM
    Comput Biol Chem; 2023 Jun; 104():107869. PubMed ID: 37068312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inducibly decreased MITF levels do not affect proliferation and phenotype switching but reduce differentiation of melanoma cells.
    Vlčková K; Vachtenheim J; Réda J; Horák P; Ondrušová L
    J Cell Mol Med; 2018 Apr; 22(4):2240-2251. PubMed ID: 29369499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.